| abstract |
The present invention relates to a pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) an EGFR inhibitor, and optionally (c) a PI3K inhibitor; the use of the combination in the treatment of a proliferative disease; A method of treating an individual of a proliferative disorder comprising administering a combination of a therapeutically effective amount. |